Atara Biotherapeutics Inc logo

ATRA - Atara Biotherapeutics Inc Share Price

$13.7 -0.1  -0.5%

Last Trade - 9:00pm

Mid Cap
Market Cap £839.9m
Enterprise Value £475.0m
Revenue £n/a
Position in Universe 2714th / 6825
Unlock ATRA Revenue
Relative Strength (%)
1m -20.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 6.39 32.6
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AtaraBiotherapeutics Inc revenues was not reported. Net lossincreased 5% to $306.6M. Higher net loss reflects OtherResearch and Development increase of 13% to $213.1M(expense), Stock-based Compensation in R&D increase of 18%to $31.5M (expense), Interest and other income decrease of48% to $2.4M (income). Basic Earnings per Share excludingExtraordinary Items increased from -$5.67 to -$4.15.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ATRA Revenue Unlock ATRA Revenue

Net Income

ATRA Net Income Unlock ATRA Revenue

Normalised EPS

ATRA Normalised EPS Unlock ATRA Revenue

PE Ratio Range

ATRA PE Ratio Range Unlock ATRA Revenue

Dividend Yield Range

ATRA Dividend Yield Range Unlock ATRA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ATRA EPS Forecasts Unlock ATRA Revenue
Profile Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated August 22, 2012
Public Since October 16, 2014
No. of Shareholders: 6
No. of Employees: 437
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 83,614,853
Free Float (0.0%)
Eligible for
ATRA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ATRA
Upcoming Events for ATRA
Wednesday 16th June, 2021 Estimate
Atara Biotherapeutics Inc Annual Shareholders Meeting
Frequently Asked Questions for Atara Biotherapeutics Inc
What is the Atara Biotherapeutics Inc share price?

As of 9:00pm, shares in Atara Biotherapeutics Inc are trading at $13.7, giving the company a market capitalisation of £839.9m. This share price information is delayed by 15 minutes.

How has the Atara Biotherapeutics Inc share price performed this year?

Shares in Atara Biotherapeutics Inc are currently trading at $13.7 and the price has moved by 61.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atara Biotherapeutics Inc price has moved by 8.55% over the past year.

What are the analyst and broker recommendations for Atara Biotherapeutics Inc?

Of the analysts with advisory recommendations for Atara Biotherapeutics Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Atara Biotherapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Atara Biotherapeutics Inc next release its financial results?

Atara Biotherapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Atara Biotherapeutics Inc dividend yield?

Atara Biotherapeutics Inc does not currently pay a dividend.

Does Atara Biotherapeutics Inc pay a dividend?

Atara Biotherapeutics Inc does not currently pay a dividend.

When does Atara Biotherapeutics Inc next pay dividends?

Atara Biotherapeutics Inc does not currently pay a dividend.

How do I buy Atara Biotherapeutics Inc shares?

To buy shares in Atara Biotherapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Atara Biotherapeutics Inc?

Shares in Atara Biotherapeutics Inc are currently trading at $13.7, giving the company a market capitalisation of £839.9m.

Where are Atara Biotherapeutics Inc shares listed? Where are Atara Biotherapeutics Inc shares listed?

Here are the trading details for Atara Biotherapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ATRA
What kind of share is Atara Biotherapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Atara Biotherapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Atara Biotherapeutics Inc share price forecast 2021?

Shares in Atara Biotherapeutics Inc are currently priced at $13.7. At that level they are trading at 0.158% discount to the analyst consensus target price of 0.00.

Analysts covering Atara Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.801 for the next financial year.

How can I tell whether the Atara Biotherapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atara Biotherapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -17.91%. At the current price of $13.7, shares in Atara Biotherapeutics Inc are trading at -16.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Atara Biotherapeutics Inc PE Ratio?

We were not able to find PE ratio data for Atara Biotherapeutics Inc.

Who are the key directors of Atara Biotherapeutics Inc?

Atara Biotherapeutics Inc's management team is headed by:

Carol Gallagher - LED
Matthew Fust - IND
Eric Dobmeier - IND
Joseph Newell - COO
Utpal Koppikar - CFO
Roy Baynes - IND
Pascal Touchon - PRE
Kristin Yarema - OTH
Ronald Renaud - CHM
K. Amar Murugan - SVP
Maria Roncarolo - DRC
Who are the major shareholders of Atara Biotherapeutics Inc?

Here are the top five shareholders of Atara Biotherapeutics Inc based on the size of their shareholding:

The Baupost Group, L.L.C. Investment Advisor/Hedge Fund
Percentage owned: 10.89% (9.11m shares)
Maverick Capital, Ltd. Hedge Fund
Percentage owned: 8.76% (7.32m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.21% (6.86m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.74% (5.64m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.73% (5.63m shares)
Similar to ATRA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.